Search
New MSK research uses saturation genome editing to better understanding of the RAD51C gene, which has been linked to higher risks of breast and ovarian cancer; sheds new light on brain metastasis; and finds a commercially available contrast dye could help surgeons better separate cancer from healthy tissue.
Discover the role of the work environment in the life and career of an employee with cancer.
An international team of researchers led by Sandra Misale, research associate at the Sloan Kettering Institute, examined the effects of the experimental cancer drug, AMG510, which targets KRAS G12C cell lines, and found that the efficacy of such KRAS G12C inhibitors is lineage-specific. These findings provide a mechanistic understanding of the differences in response to KRAS G12C inhibitor in lung and colorectal cancers.
Memorial Sloan Kettering Cancer Center (MSK) has been recognized by the American College of Surgeons (ACS) for its commitment to providing optimal surgical care for children and adolescents.
Learn how Randy Reif got state-of-the-art care for a benign brain tumor at Memorial Sloan Kettering Cancer Center.
A team of experts at MSK shared their insights on managing blood cancer or a bone marrow transplant in a recent Information Session.
Scott W. Lowe has joined Memorial Sloan Kettering Cancer Center as a member of the Cancer Biology and Genetics Program in the Sloan Kettering Institute and Chair of the Geoffrey Beene Cancer Research Center.
A new therapy tested in mouse models appears to harness neutrophils, a type of white blood cell, to effectively prevent the spread of breast cancer cells.
June’s “MSK Science Spotlight” segments kick off on Monday, June 1, featuring the honoree of the Katharine Berkan Judd Award Lectureship, Ron Vale, PhD, Vice President and Executive Director, Janelia Research Campus at the Howard Hughes Medical Institute.
Adding immunotherapy to standard treatment both before and after surgery significantly improved outcomes for people with gastric and gastroesophageal adenocarcinoma (G/GEA), according to experts from Memorial Sloan Kettering Cancer Center (MSK). Results from the MATTERHORN trial, a global phase three study, were presented today at the annual American Society of Clinical Oncology meeting and simultaneously published in the New England Journal of Medicine (NEJM).